The use of hyaluronic acid in vulvovaginal atrophy in women after antitumor therapy

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Objective: To analyze the available literature on the use of hyaluronic acid in programs of non-hormonal correction of vulvovaginal disorders associated with antitumor treatment in cancer patients.

Materials and methods: The literature search was conducted in the electronic databases, namely PubMed, Scopus, Web of Science, Cochrane Library, ScienceDirect, Embase, PsycINFO using the keywords in Russian and English. The articles were published between 1914 and 2024.

Results: The symptoms of genitourinary syndrome of menopause have a long-term negative impact on the quality of life of women who underwent antitumor treatment. Currently, it is important to develop approaches to supportive and restorative therapy for women at risk of developing genitourinary syndrome of menopause. One of the effective methods for correcting this condition in women undergoing oncological rehabilitation is the use of intravaginal preparations containing hyaluronic acid. These preparations significantly reduce the symptoms of vulvovaginal atrophy with efficacy comparable to that of topical estrogens. Besides, they have high safety and do not cause side effects.

Conclusion: The analysis of the literature showed the potential for further research into the efficacy and safety of using hyaluronic acid to correct vulvovaginal changes in cancer patients after antitumor therapy, as well as for long-term follow-up. This research could help determine whether it should be included in the standard restorative treatment for these patients. Such an approach could improve the quality of life for this patient group and address a number of psychological and socio-economic issues.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Liana Mkrtchyan

Tsyb Medical Radiological Research Centre of the National Medical Research Centre for Radiology; Obninsk Institute for Nuclear Power Engineering of the Moscow Engineering Physics Institute

Хат алмасуға жауапты Автор.
Email: liana6969@mail.ru
ORCID iD: 0000-0002-5027-5331

Dr. Med. Sci., Head of the Department of Medical Rehabilitation and Rehabilitation Technologies; Professor at the Department of Obstetrics and Gynecology

Ресей, 4, Korolyov St., Obninsk, Kaluga Region, 249036; 1, Studgorodok, Obninsk, Kaluga Region, 249040

Marina Kukosh

Tsyb Medical Radiological Research Centre of the National Medical Research Centre for Radiology; Patrice Lumumba Peoples’ Friendship University of Russia

Email: manja70@inbox.ru
ORCID iD: 0000-0001-6481-1724

PhD, Senior Researcher at the Department of Medical Rehabilitation and Rehabilitation Technologies; Associate Professor at the Department of Oncology and Hematology of the Medical Institute

Ресей, 4, Korolyov St., Obninsk, Kaluga Region, 249036; 21, Miklukho-Maklay St., Moscow, 117198

Anastasia Bychkova

Tsyb Medical Radiological Research Centre of the National Medical Research Centre for Radiology; Academician Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology

Email: a_bychkova88@mail.ru
ORCID iD: 0000-0003-4855-8188

PhD Student; Obstetrician-Gynecologist, Oncologist at the Department of Aesthetic Gynecology and Rehabilitation

Ресей, 4, Korolyov St., Obninsk, Kaluga Region, 249036; 4, Academic Oparin St., Moscow, 117997

Inna Apolikhina

Academician Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology; Sechenov First Moscow State Medical University

Email: i_apolikhina@oparina4.ru
ORCID iD: 0000-0002-4581-6295

Dr. Med. Sci., Professor, Head of the Department of Aesthetic Gynecology and Rehabilitation; Professor at the Department of Obstetrics, Gynecology, Perinatology and Reproductology of the Institute of Vocational Education

Ресей, 4, Academic Oparin St., Moscow, 117997; Bldg. 2, 8, Trubetskaya St., Moscow, 119991

Sergey Ivanov

Tsyb Medical Radiological Research Centre of the National Medical Research Centre for Radiology; Patrice Lumumba Peoples’ Friendship University of Russia

Email: oncourolog@gmail.com
ORCID iD: 0000-0001-7689-6032

Dr. Med. Sci., Corresponding Member of the RAS, Director; Professor at the Kharchenko Department of Oncology and Radiology of the Medical Institute

Ресей, 4, Korolyov St., Obninsk, Kaluga Region, 249036; 8, Miklukho-Maklay St., Moscow, 117198

Andrey Kaprin

Patrice Lumumba Peoples’ Friendship University of Russia; Herzen Moscow Research Institute of Oncology of the National Medical Research Centre for Radiology; National Medical Research Centre for Radiology

Email: kaprin@mail.ru
ORCID iD: 0000-0001-8784-8415

Dr. Med. Sci., Professor, Academician of the RAS, Academician of the Russian Academy of Education, Head of the Kharchenko Department of Oncology and Radiology of the Medical Institute; Director; General Director

Ресей, 8, Miklukho-Maklay St., Moscow, 117198; 3, 2nd Botkinsky Dr., Moscow, 125284; 3, 2nd Botkinsky Dr., Moscow, 125284

Irina Zamulaeva

Tsyb Medical Radiological Research Centre of the National Medical Research Centre for Radiology

Email: zamulaeva@mail.ru
ORCID iD: 0000-0002-6136-8445

Dr. Sci. (Bio), Professor, Head of the Department of Radiation Biochemistry

Ресей, 4, Korolyov St., Obninsk, Kaluga Region, 249036

Әдебиет тізімі

  1. Pérez-López F.R., Phillips N., Vieira-Baptista P., Cohen-Sacher B., Fialho S.C.A.V., Stockdale C.K. Management of postmenopausal vulvovaginal atrophy: recommendations of the International society for the study of vulvovaginal disease. Gynecol. Endocrinol. 2021; 37(8): 746-52.https://dx.doi.org/10.1080/09513590.2021.1943346
  2. Lev-Sagie A. Vulvar and vaginal atrophy: physiology, clinical presentation, and treatment considerations. Clin. Obs. Gynecol. 2015; 58(3): 476-91. https://dx.doi.org/10.1097/GRF.0000000000000126
  3. Gliniewicz K., Schneider G.M., Ridenhour B.J., Williams C.J., Song Y., Farage M.A. et al. Comparison of the vaginal microbiomes of premenopausal and postmenopausal women. Front. Microbiol. 2019; 10: 193. https:// dx.doi.org/10.3389/fmicb.2019.00193
  4. Brotman R.M., Shardell M.D., Gajer P., Fadrosh D., Chang K., Silver M.I. et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause. 2014; 21: 450-8. https://dx.doi.org/10.1097/GME.0b013e3182a4690b
  5. Nappi R.E., Cucinella L., Martini E., Cassani C. The role of hormone therapy in urogenital health after menopause. Best Pract. Res. Clin. Endocrinol. Metab. 2021; 35: 101595. https://dx.doi.org/10.1016/j.beem.2021.101595
  6. Escobar C., Rosenblum N. Vaginal estrogen-what a urologist should know. Urology. 2021; 151: 37-43. https://dx.doi.org/10.1016/j.urology.2020.05.034
  7. Cox P., Panay N. Vulvovaginal atrophy in women after cancer. Climacteric. 2019; 22(6): 565-71. https://dx.doi.org/10.1080/13697137.2019.1643180
  8. The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020; 27(9): 976-92. https:// dx.doi.org/10.1097/GME.0000000000001609
  9. Gambacciani M. Managing vulvovaginal atrophy after breast cancer. Post Reprod. Health. 2019; 25(3): 167-8. https://dx.doi.org/10.1177/2053369119848884
  10. Meriggiola M.C., Villa P., Maffei S., Becorpi A., Di Paolantonio T., Nicolucci A. et al. Vulvovaginal atrophy in women with and without a history of breast cancer: baseline data from the Patient satisfaction study (PEONY) in Italy. Maturitas. 2024; 183: 107950. https://dx.doi.org/10.1016/j.maturitas.2024.107950
  11. Guidozzi F. Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation. Climacteric. 2016; 19(5): 419-22. https://dx.doi.org/10.1080/13697137.2016.1209396
  12. Kelsey T.W., Hua C.H., Wyatt A., Indelicato D., Wallace W.H. A predictive model of the effect of therapeutic radiation on the human ovary. PLOS One. 2022; 17(11): e0277052. https://dx.doi.org/10.1371/journal.pone.0277052
  13. Huang Y., Qin T., Yang M., Liu Z. Impact of ovary-sparing treatment planning on plan quality, treatment time and gamma passing rates in intensity-modulated radiotherapy for stage I/II cervical cancer. Medicine (Baltimore). 2023; 102(50): e36373. https://dx.doi.org/10.1097/MD.0000000000036373
  14. Moss E.L., Taneja S., Munir F., Kent C., Robinson L., Potdar N. et al. Iatrogenic menopause after treatment for cervical cancer. Clin. Oncol. (R. Coll. Radiol.). 2016; 28(12): 766-75. https://dx.doi.org/10.1016/j.clon.2016.08.016
  15. Panay N., Fenton A. Iatrogenic menopause following gynecological malignancy: time for action! Climacteric. 2016; 19(1): 1-2. https://dx.doi.org/10.3109/ 13697137.2015.1127640
  16. Kollberg K.S., Waldenström A.-C., Bergmark K., Dunberger G., Rossander A., Wilderäng U. et al. Reduced vaginal elasticity, reduced lubrication, and deep and superficial dyspareunia in irradiated gynecological cancer survivors. Acta Oncol. 2015; 54(5): 772-9. https://dx.doi.org/10.3109/0284186X.2014.1001036
  17. Jensen P.T., Froeding L.P. Pelvic radiotherapy and sexual function in women. Transl. Androl. Urol. 2015; 4(2): 186-205. https://dx.doi.org/10.3978/ j.issn.2223-4683.2015.04.06
  18. Джанашвили Л.Г., Назаренко Т.А., Балахонцева О.С., Мартиросян Я.О., Пронин С.М., Калинина Е.А., Бирюков А.М. Реализация репродуктивной функции у больных с атипической гиперплазией и раком эндометрия I стадии. Акушерство и гинекология. 2020; 4: 45-51. [Dzhanashvili L.G., Nazarenko T.A., Balakhontseva O.S., Martirosyan Ya.O., Pronin S.M., Kalinina E.A., Biryukova A.M. Realization of reproductive potential in patients with atypical hyperplasia and stage I endometrial cancer. Obstetrics and Gynecology. 2020; (4): 45-51 (in Russian)]. https://dx.doi.org/10.18565/aig.2020.4.45-51
  19. Кутаков Н.М., Чекини Д.А. Перспективы и возможности сохранения репродуктивной функции у больных, получающих противоопухолевое лечение. Клиническое наблюдение. MD-Onco. 2023; 3(2): 16-9. [Kutakov N.M., Chekini D.A. Perspectives and possibilities of preserving reproductive function in patients receiving antitumor treatment. Clinical observation. MD-Onco. 2023; 3(2): 16-9 (in Russian)]. https:// dx.doi.org/10.17650/ 2782-3202-2023-3-2-16-19
  20. Назаренко Т.А., Сухих Г.Т., ред. Сохранение репродуктивной функции онкологических больных. Руководство для врачей. М.: МЕДпресс-информ; 2022. 160 с. [Nazarenko T.A., Sukhikh G.T., eds. Preservation of reproductive function in cancer patients. Manual for physicians. Moscow: MEDpress-Inform; 2022. 160 p. (in Russian)].
  21. Claes M., Tuts L., Robijns J., Mulders K., Van De Werf E., Bulens P. et al. Cancer therapy-related vaginal toxicity: its prevalence and assessment methods – a systematic review. J. Cancer Surviv. 2024; 19: 1293-312. https:// dx.doi.org/10.1007/s11764-024-01553-y
  22. Cotangco K., Class Q.A., Johnson T.P., Kothari R. Cervical cancer survivors’ attitudes and understanding of menopause and hormone therapy. Menopause. 2020; 27(6): 701-5. https://dx.doi.org/10.1097/GME.0000000000001520
  23. Hofsjö A., Bergmark K., Blomgren B., Jahren H., Bohm-Starke N. Radiotherapy for cervical cancer – impact on the vaginal epithelium and sexual function. Acta Oncol. 2018; 57(3): 338-45. https://dx.doi.org/10.1080/ 0284186X.2017.1400684
  24. Tramacere F., Lancellotta V., Casà C., Fionda B., Cornacchione P., Mazzarella C. et al. Assessment of sexual dysfunction in cervical cancer patients after different treatment modality: a systematic review. Medicina (Kaunas). 2022; 58(9): 1223. https://doi.org/10.3390/ medicina58091223
  25. Kirchheiner K., Smet S., Jürgenliemk-Schulz I.M., Haie-Meder C., Chargari C., Lindegaard J.C. et al. Impact of vaginal symptoms and hormonal replacement therapy on sexual outcomes after definitive chemoradiotherapy in patients with locally advanced cervical cancer: results from the EMBRACE-I study. Int. J. Radiat. Oncol. Biol. Phys. 2022; 112(2): 400-13. https://doi.org/10.1016/ j.ijrobp.2021.08.036
  26. Мкртчян Л.С., Иванов С.А., Кулиева Г.З.К., Замулаева И.А., Крикунова Л.И. Улучшение качества жизни больных раком шейки матки после лучевой т химиолучевой терапии. Радиация и риск (Бюллетень НРЭР). 2020; 1(29): 120-8. [Mkrtchian L.S., Ivanov S.A., Kulieva G.Z.K., Zamulaeva I.A., Krikunova L.I. Quality of life of patients with cervical cancer after radiotherapy and chemoradiotherapy. Radiation and risk. 2020; 1(29): 120-8 (in Russian)]. https://dx.doi.org/10.21870/ 0131-3878-2020-29-1-120-128
  27. Rees M., Angioli R., Coleman R.L., Glasspool R., Plotti F., Simoncini T. et al. European menopause and andropause society (EMAS) and International gynecologic cancer society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. Maturitas. 2020; 134: 56-61. https://dx.doi.org/10.1016/ j.maturitas.2020.01.005
  28. Filippini M., Porcari I., Ruffolo A.F., Casiraghi A., Farinelli M., Uccella S. et al. CO2-Laser therapy and genitourinary syndrome of menopause: a systematic review and meta-analysis. J. Sex. Med. 2022; 19(3): 452-70. https:// dx.doi.org/10.1016/j.jsxm.2021.12.010
  29. Benini V., Ruffolo A.F., Casiraghi A., Degliuomini R.S., Frigerio M., Braga A. et al. New innovations for the treatment of vulvovaginal atrophy: an up-to-date review. Medicina (Kaunas). 2022; 58(6): 770. https://dx.doi.org/10.3390/medicina58060770
  30. Desai S.A., Kroumpouzos G., Sadick N. Vaginal rejuvenation: from scalpel to wands. Int. J. Womens Dermatol. 2019; 5(2): 79-84. https:// dx.doi.org/10.1016/j.ijwd.2019.02.003
  31. Cox P., Panay N. Non-hormonal treatments for managing vulvovaginal atrophy/genitourinary syndrome of menopause. Climacteric. 2023; 26(4): 367-72. https://dx.doi.org/10.1080/13697137.2023.2210283
  32. Woopen H., Sehouli J., Davis A., Lee Y.C. , Cohen P.A., Ferrero A. et al. GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: a position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee. Cancer Treat. Rev. 2022; 107: 102396. https:// dx.doi.org/10.1016/j.ctrv.2022.102396
  33. Faubion S.S., Larkin L.C., Stuenkel C.A., Bachmann G.A., Chism L.A., Kagan R. et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: Consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health. Menopause. 2018; 25(6): 596-608. https:// dx.doi.org/10.1097/GME.0000000000001121
  34. Kuhle C.L., Kapoor E., Sood R., Thielen J.M., Jatoi A., Faubion S.S. Menopausal hormone therapy in cancer survivors: a narrative review of the literature. Maturitas. 2016; 92: 86-96. https://dx.doi.org/10.1016/ j.maturitas.2016.07.018
  35. Sassarini J., Perera M., Spowart K., McAllister K., Fraser J., Glasspool R. et al. Managing vulvovaginal atrophy after breast cancer. Post Reprod. Health. 2018; 24(4): 163-5. https://dx.doi.org/10.1177/2053369118805344
  36. Министерство здравоохранения Российской Федерация. Клинические рекомендации. Менопауза и климактерическое состояние у женщины. М.; 2024. 93 с. [Ministry of Health of the Russian Federation. Clinical guidelines. Menopause and menopause in women. Moscow; 2024. 93 p. (in Russian)].
  37. Marès P., Jauffret C., Martin C., Lopes P., Coussy F. Genitourinary syndrome of menopause in patients with breast cancer treated by hormonotherapy: women's perception in ITAC, a French web-based survey. Bull. Cancer. 2024; 111(4): 347-55. https://dx.doi.org/10.1016/ j.bulcan.2023.08.014
  38. Pruthi S., Simon J.A., Early A.P. Current overview of the management of urogenital atrophy in women with breast cancer. Breast J. 2011; 17(4): 403-8. https://dx.doi.org/10.1111/j.1524-4741.2011.01089.x
  39. Faubion S.S., Larkin L.C., Stuenkel C.A., Bachmann G.A., Chism L.A., Kagan R. et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health. Menopause. 2018; 25(6): 596-608. https:// dx.doi.org/10.1097/GME.0000000000001121
  40. Concin N., Matias-Guiu X., Vergote I., Cibula D., Mirza M.R., Marnitz S. et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int. J. Gynecol. Cancer. 2021; 31(1): 12-39. https:// dx.doi.org/10.1136/ijgc-2020-002230
  41. Chargari C., Tanderup K., Planchamp F., Chiva L., Humphrey P., Sturdza A. et al. ESGO / ESTRO quality indicators for radiation therapy of cervical cancer. Int. J. Gynecol. Cancer. 2023; 33(6): 862-75. https://dx.doi.org/10.1136/ ijgc-2022-004180
  42. Dicker K.T., Gurski L.A., Pradhan-Bhatt S., Witt R.L., Farach-Carson M.C., Jia X. Hyaluronan: a simple polysaccharide with diverse biological functions. Acta Biomater. 2014; 10(4): 1558-70. https://dx.doi.org/10.1016/ j.actbio.2013.12.019
  43. Al Ghanim K., Jaszkul K.M., Simpson A., Turley E.A. Association of squamous cell carcinoma and hyaluronan: a scope of the literature. Eplasty. 2024; 24: e11.
  44. Tavianatou A.G., Caon I., Franchi M., Piperigkou Z., Galesso D., Karamanos N.K. Hyaluronan: molecular size-dependent signaling and biological functions in inflammation and cancer. FEBS J. 2019; 286(15): 2883-2908. https:// dx.doi.org/10.1111/febs.14777
  45. Fallacara A., Baldini E., Manfredini S., Vertuani S. Hyaluronic acid in the third millennium. Polymers (Basel). 2018; 10(7): 701. https://dx.doi.org/10.3390/polym10070701
  46. Garantziotis S., Savani R.C. Hyaluronan biology: a complex balancing act of structure, function, location and context. Matrix Biol. 2019; 78-79: 1-10. https://dx.doi.org/10.1016/j.matbio.2019.02.002
  47. Parnigoni A., Moretto P., Rovera S., Viola M., Karousou E., Passi A. et al. Particle exclusion assay: a tool for measuring hyaluronan pericellular matrix. Methods Mol. Biol. 2023; 2619: 53-60. https://dx.doi.org/10.1007/978-1-0716-2946-8_4
  48. Tolg C., Messam B.J., McCarthy J.B., Nelson A.C., Turley E.A. Hyaluronan functions in wound repair that are captured to fuel breast cancer progression. Biomolecules. 2021; 11(11): 1551. https://dx.doi.org/10.3390/biom11111551
  49. Price Z.K., Lokman N.A., Ricciardelli C. Differing roles of hyaluronan molecular weight on cancer cell behavior and chemotherapy resistance. Cancers (Basel). 2018; 10(12): 482. https://dx.doi.org/10.3390/cancers10120482
  50. Albtoush N., Queisser K.A., Zawerton A., Lauer M.E., Beswick E.J., Petrey A.C. TSG6 hyaluronan matrix remodeling dampens the inflammatory response during colitis. Matrix Biol. 2023; 121: 149-66. https://dx.doi.org/10.1016/ j.matbio.2023.06.007
  51. Triggs-Raine B., Natowicz M.R. Biology of hyaluronan: insights from genetic disorders of hyaluronan metabolism. World J. Biol. Chem. 2015; 6(3): 110-20. https://dx.doi.org/10.4331/wjbc.v6.i3.110
  52. Шнайдер Н.А., Дюжакова А.В., Вайман Е.Э., Никитина Е.И., Борзых О.Б., Насырова Р.Ф. Значение генетических факторов метаболизма эндогенной гиалуроновой кислоты в поддержании гомеостаза кожи. Вестник дерматологии и венерологии. 2021; 97(3): 24-38. [Shnayder N.A., Dyuzhakova A.V., Vaiman E.E., Nikitina E.I., Borzykh O.B., Nasyrova R.F. The role of genetic factors of endogenous hyaluronic acid metabolism in maintaining skin homeostasis. Vestnik dermatologii i venerologii. 2021; 97(3): 24-38 (in Russian)]. https://dx.doi.org/10.25208/vdv1193
  53. Kobayashi T., Chanmee T., Itano N. Hyaluronan: metabolism and function. Biomolecules. 2020; 10(11): 1525. https://dx.doi.org/10.3390/biom10111525
  54. Cirillo N. The hyaluronan/CD44 axis: a double-edged sword in cancer. Int. J. Mol. Sci. 2023; 24(21): 15812. https://dx.doi.org/10.3390/ijms242115812
  55. Матчук О.Н., Замулаева И.А. Количественные изменения популяции стволовых клеток рака шейки матки линии Hela под влиянием фракционированного γ-облучения in vitro. Радиация и риск. 2019; 28(2): 112-23. [Matchuk O.N., Zamulaeva I.A. Quantitative changes in the stem cell population of cervical cancer cell line HeLa under the influence of fractionated γ-irradiation in vitro. Radiation and risk. 2019; 28(2): 112-23 (in Russian)]. https://dx.doi.org/10.21870/0131-3878-2019-28-2-112-123
  56. Замулаева И.А., Матчук О.Н., Селиванова Е.И., Андреев В.Г., Липунов Н.М., Макаренко С.А., Жаворонков Л.П., Саенко А.С. Увеличение количества опухолевых стволовых клеток под воздействием редкоионизирующего излучения. Радиационная биология. Радиоэкология. 2014; 54(3): 256-64. [Zamulaeva I.A., Matchuk O.N., Selivanova E.I., Andreev V.G., Lipunov N.M., Makarenko S.A., Zhavoronkov L.P., Saenko A.S. Increase in the number of cancer stem cells after exposure to low-LET radiation. Radiats Biol. Radioecol. 2014; 54(3): 256-64 (in Russian)]. https://dx.doi.org/10.7868/S0869803114030187
  57. Peitzch C., Kurth I., Ebert N., Dubrovska A., Baumann M. Cancer stem cells in radiation response: current views and future perspectives in radiation oncology. Int. J. Radiat. Biol. 2019; 95(7): 900-11. https://dx.doi.org/10.1080/ 09553002.2019.1589023
  58. Phi L., Sari I., Yang Y.-G., Lee S.-H., Jun N., Kim K.S. et al. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int. 2018; 2018: 5416923. https://dx.doi.org/10.1155/2018/ 5416923
  59. Zamulaeva I.A., Selivanova E.I., Matchuk O.N., Krikunova L.I., Mkrtchyan L.S., Kulieva G.Z. et al. Quantitative changes in the population of cancer stem cells after radiation exposure in a dose of 10 gy as a prognostic marker of immediate results of the treatment of squamous cell cervical cancer. Bull. Exp. Biol. Med. 2019; 168(1): 156-9. https://dx.doi.org/10.1007/s10517-019-04667-x
  60. Zamulaeva I., Matchuk O., Selivanova E., Mkrtchian L., Yakimova A., Gusarova V. et al. Effects of fractionated radiation exposure on vimentin expression in cervical cancers: analysis of association with cancer stem cell response and short-term prognosis. Int. J. Mol. Sci. 2023; 24(4): 3271. https://dx.doi.org/10.3390/ijms24043271
  61. Lytle N.K., Barber A.G., Reya T. Stem cells fate in cancer growth, progression and therapy resistance. Nat. Rev. Cancer. 2018; 18(11): 669-80. https:// dx.doi.org/10.1038/s41568-018-0056-x
  62. Palomeras S., Ruiz-Martínez S., Puig T. Targeting breast cancer stem cells to overcome treatment resistance. Molecules. 2018; 23(9): 2193. https:// dx.doi.org/10.3390/molecules23092193
  63. Luo M., Clouthier S.G., Deol Y., Liu S., Nagrath S., Azizi E. et al. Breast cancer stem cells: current advances and clinical implications. Methods Mol Biol. 2015; 1293: 1-49. https://dx.doi.org/10.1007/978-1-4939-2519-3_1
  64. Yang F., Xu J., Tang L., Guan X. Breast cancer stem cell: the roles and therapeutic implications. Cell. Mol. Life Sci. 2017; 74(6): 951-66. https://dx.doi.org/10.1007/s00018-016-2334-7
  65. Chanmee T., Ontong P., Kimata K., Itano N. Key roles of hyaluronan and its CD44 receptor in the stemness and survival of cancer stem cells. Front. Oncol. 2015; 5: 180. https://dx.doi.org/10.3389/fonc.2015.00180
  66. Bourguignon L.Y.W., Shiina M., Li J.J. Hyaluronan-CD44 interaction promotes oncogenic signaling, microRNA functions, chemoresistance, and radiation resistance in cancer stem cells leading to tumor progression. Adv. Cancer Res. 2014; 123: 255-75. https://dx.doi.org/10.1016/ B978-0-12-800092-2.00010-1
  67. Киселёва М.В., Замулаева И.А., Радзинский В.Е., Оразов М.Р., Долгов Е.Д., Иванов С.А., Каприн А.Д. Новый метод лечения вульвовагинальной атрофии у пациенток с отягощенным онкологическим анамнезом. Вопросы гинекологии, акушерства и перинатологии. 2024; 23(3):111-7. [Kiseleva M.V., Zamulaeva I.A., Radzinsky V.E., Orazov M.R., Dolgov E.D., Ivanov S.A., Kaprin A.D. New therapeutic approach to vulvovaginal atrophy in patients with a history of cancer. Gynecology, Obstetrics and Perinatology. 2024; 23(3): 111-7 (in Russian)]. https://dx.doi.org/10.20953/ 1726-1678-2024-3-111-117
  68. Liu Z., Hou P., Fang J., Shao C., Shi Y., Melino G. et al. Hyaluronic acid metabolism and chemotherapy resistance: recent advances and therapeutic potential. Mol. Oncol. 2024; 18(9): 2087-2106. https://dx.doi.org/10.1002/ 1878-0261.13551
  69. Bourguignon L.Y.W., Earle C., Shiina M. Hyaluronan-CD44 interaction promotes HPV 16 E6 oncogene-mediated oropharyngeal cell carcinoma survival and chemoresistance. Matrix Biol. 2019; 78-79: 180-200. https://dx.doi.org/10.1016/j.matbio.2018.07.008
  70. Cascone S., Lamberti G. Hydrogel-based commercial products for biomedical applications: a review. Int. J. Pharm. 2020; 573: 118803. https:// dx.doi.org/10.1016/j.ijpharm.2019.118803

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу
2. Fig. 1. Modern methods of correction of GUMs, including vulvovaginal atrophy, stress incontinence, pelvic floor muscle dysfunction

Жүктеу (204KB)
Метадеректер
3. Fig. 2. Molecular structure of the disaccharide unit of HA [46]

Жүктеу (77KB)
Метадеректер
4. Fig. 3. Influence of the size of the GC molecule on interaction with receptors and biological effects (adapted from [44])

Жүктеу (440KB)
Метадеректер
5. Fig. 4. Influence of GC interaction with CD44 on some properties of tumour cells, leading to the emergence/increase of resistance of TNF to antitumour agents and enhancement of metastasis processes (figure by the authors)

Жүктеу (137KB)
Метадеректер

© Bionika Media, 2025